联合检测AnuA、ANA、抗ds-DNA、抗ENA在SLE患者中的临床应用

Clinical Application of Combined Detection of AnuA,ANA,anti ds-DNA and antiENA in SLE Patients

目的联合检测SLE患者的多种自身抗体,为临床诊疗提供依据。方法免疫印迹法检测120例SLE患者AnuA、抗Sm、抗SSA、抗SSB、抗Rib,间接免疫荧光法(IIF)检测抗ds-DNA和ANA,60例健康体检者做为对照组。结果SLE患者ANA、抗ds-DNA、AunA、抗Sm、抗SSA、抗SSB和抗Rib阳性率分别为69.2%、70.8%、74.2%、35.0%、42.5%、11.7%和26.7%。活动期ANA、抗ds-DNA和AunA阳性率分别为90.7%、98.1%和83.3%,非活动期分别为51.5%、48.5%和66.7%,三项指标差异均有统计学意义(P<0.01、P<0.01和P<0.05)。60例对照组各项检测结果均为阴性。结论联合检测SLE多种自身抗体在提高SLE的诊断分型及疗效评价等方面具有重要意义。

Objective To combine detection of SLE patients with a variety of autoantibodies,provide a basis for clinical diagnose and treat- ment. Methods AnuA,anti-Sm,anti-SSA,anti-SSB and anti-Rib were determined by western blotting,and anti-ds-DNA and ANA were determined by indirect immunofluorescence（IIF） in 120 cases of SLE patients and 60 controls. Results The positive rates of ANA, anti ds-DNA, AunA, anti-Sm, anti-SSA, anti-SSB and anti-Rib was 69.2%, 70.8%, 74.2%, 35%, 42.5%, 11.7% and 26.7% in SLE patients. The positive rates of ANA, anti ds-DNA and AunA was 90.7%,98.1% and 83.3% in patients with active stage of SLE. The positive rates of ANA, anti ds-DNA and AunA was 51.5%,48.5% and 66.7% in patients with inactive stage of SLE. Three indicators had statistically significance in active stage and inactive stage（P〈 0.01 ,P〈 0.01 and P〈 0.05）. All of the test results of 60 controls were negative. Conclusion Combined detection of several autoantibody was important to diagnosis and curative evaluation in SLE.